A5002109641- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Neutropenia and Cancer Infections
- CAR-T cell therapy research
- Renal Transplantation Outcomes and Treatments
- Cancer Immunotherapy and Biomarkers
- Polyomavirus and related diseases
- Lung Cancer Treatments and Mutations
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immune Cell Function and Interaction
- Clostridium difficile and Clostridium perfringens research
- Transplantation: Methods and Outcomes
- Gut microbiota and health
- Eosinophilic Disorders and Syndromes
- Fungal Infections and Studies
- Mycobacterium research and diagnosis
- Antifungal resistance and susceptibility
- T-cell and B-cell Immunology
- COVID-19 Clinical Research Studies
- Amyloidosis: Diagnosis, Treatment, Outcomes
- CNS Lymphoma Diagnosis and Treatment
First Pavlov State Medical University of St. Petersburg
2016-2025
European Society for Blood and Marrow Transplantation
2023-2024
Inserm
2024
Sorbonne Université
2024
St Petersburg University
2023
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
2019-2022
Charles University
2022
Jacobi Medical Center
2021
The Bronx Defenders
2021
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
2021
Clinical efficacy of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis has been demonstrated in haploidentical and HLA-matched bone marrow but not unrelated peripheral blood stem cell (PBSC) transplantations. Also, no direct comparisons have published with current standard care, combination antithymocyte globulin (ATG), calcineurin inhibitors, either methotrexate or mycophenolate mofetil (MMF). Eighty-six adult patients (median age 34 years; range,...
There is an increased risk of GVHD and non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) when mismatched unrelated donors (MMUD) are used. In Europe, it standard practice to use rabbit anti-thymocyte globulin (rATG) reduce the high NRM risks MMUD alloSCT. As alternative rATG, post-transplantation Cyclophosphamide (PTCy) in increasing clinical use. It currently impossible give general recommendations regarding preference for one method over another since...
Abstract There is a high risk of GVHD and non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) from unrelated donors. Prophylaxis with rabbit anti-thymocyte globulin (rATG) standard in Europe but post-transplantation Cyclophosphamide (PTCy) an emerging alternative. We analyzed outcomes rATG ( n = 7725) vs. PTCy 1039) prophylaxis adult patients hematologic malignancies undergoing peripheral blood alloSCT 10/10 antigen-matched donors (MUD) between January 2018 June...
Fecal microbiota transplantation (FMT) has been recently approved by FDA for the treatment of refractory recurrent clostridial colitis (rCDI). Success FTM in rCDI led to a number studies investigating effectiveness its application other gastrointestinal diseases. However, majority effects FMT were evaluated on patients with initially altered microbiota. The aim our study was estimate gut composition healthy volunteers and monitor long-term outcomes.We have performed combined analysis three...
We investigated the incidence and outcome of anti-CD19 chimeric antigen receptor (CAR) T-cells-associated Common Terminology Criteria for Adverse Events (CTCAE) ≥grade 3 cytopenia. In EBMT CAR-T registry, we identified 398 adult patients with large B-cell lymphoma who had been treated CAR-T-cells axicel (62%) or tisacel (38%) before August 2021 cytopenia status documented first 100 days. Most received two three previous lines therapy, however, 22.3% four more. Disease was progressive in...
Abstract Ruxolitinib has become the new standard of care for steroid-refractory and steroid-dependent chronic GVHD (SR-cGVHD). Our aim was to collect comparative data between ruxolitinib extracorporeal photophoresis (ECP). We asked EBMT centers if they were willing provide detailed information on grading, -therapy, -dosing, -response complications each included patient. 31 responded positively we all patients 1/2017-7/2019 treated with ECP or moderate severe SR-cGVHD. identified 84 57...
The pilot clinical study presented demonstrates the possibility, safety, and effectiveness of oral microbiota transplantation from a healthy donor to patient with neuroblastoma prevent chemotherapy-induced mucositis. A 6-month-old diagnosis retroperitoneal was treated according NB 2004 protocol. Due development severe mucositis, it decided perform transplantation. During next 3 chemotherapy cycles conditioning regimen before autologous hematopoietic cell (auto-HCT), repeatedly injected per...
The timing of immunosuppressive therapy used in combination with post-transplantation cyclophosphamide (PTCY) haploidentical hematopoietic stem cell transplant (haplo-HSCT) is not standardized. We evaluated the schedules immunosuppression after haplo-HSCT 509 patients acute leukemia receiving PTCY on days +3 and +4 along tacrolimus (group 1; n = 215), cyclosporine A (CSA) mycophenolate mofetil (MMF) from day +5 2; 170), or CSA + MMF 0 1 3; 124). Compared other 2 groups, group 3 were younger...
We previously reported that the "Endothelial Activation and Stress Index" (EASIX; ((creatinine×lactate dehydrogenase)÷thrombocytes)) measured before start of conditioning predicts mortality after allogeneic hematopoietic stem cell transplantation (alloSCT) when used as continuous score. For broad clinical implementation, a prospectively validated EASIX-pre cut-off is needed defines high-risk cohort easy to use. In current study, we first performed retrospective analysis in n=2022 alloSCT...
Abstract It has been reported in prospective randomized trials that antithymocyte globulin (ATG)–based graft-versus-host disease (GVHD) prophylaxis benefits the setting of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with unrelated donors (UDs). However, optimal GVHD strategy challenged recently by increasing use posttransplant cyclophosphamide (PTCY). We report from European Society for Blood and Marrow Transplantation registry outcomes 960 patients myelodysplastic...
Background. FMS‑like tyrosine kinase 3 (FLT3) gene mutations are the most frequently detected genetic aberrations in adult patients with newly diagnosed acute myeloid leukemia (AML), identified approximately 30 % of patients. The addition midostaurin, an FLT3 inhibitor, to standard therapy and after allogeneic hematopoietic stem cell transplantation (allo‑HSCT) improves overall (OS) event‑free survival (EFS). Aim. To evaluate effect adding midostaurin FLT3‑mutated AML. impact allo‑HSCT...
Background. Haploidentical hematopoietic stem cell transplantation (haplo‑HSCT) represents an important alternative for patients with acute myeloid leukemia (AML) who lack HLA‑matched donor. However, the high incidence of primary graft failure remains a significant challenge. Optimizing strategies, including selection source and modification conditioning regimens, may improve haplo‑HSCT outcomes. Aim. To evaluate results in AML first remission, focusing on engraftment rates factors...
Background Hematopoietic stem cell transplantation (HSCT) offers a potential cure for various hematologic malignancies and non-malignant disorders but is often accompanied by severe complications, one of the most challenging being transplant-associated thrombotic microangiopathy (TA-TMA). Eculizumab, complement inhibitor, has emerged as an effective therapeutic option TA-TMA. Methods This single-center retrospective study was conducted at Pavlov University, St. Petersburg, to evaluate...
Abstract Rabbit anti-thymocyte globulin (rATG) reduced chronic GVHD after matched related donor (MRD) allogeneic stem cell transplantation (alloSCT) from 69% to 32% in a randomized trial and is the recommended standard Europe. Post-transplantation Cyclophosphamide (PTCy) an emerging alternative but lacks such solid data MRD alloSCT. We therefore analyzed outcomes of rATG ( n = 4140) vs. PTCy 1069) adult patients with hematologic malignancies undergoing alloSCT between 2017 2021 EBMT...
Mesenchymal stem cells (MSCs) are widely used in cell therapy due to their convenience, multiline differentiation potential, reproducible protocols, and biological properties. The potential of MSCs impregnate magnetic microcapsules possible influence on function ability response field have been explored. Interestingly, the suspended media show much higher internalization microcapsules, then adhere into surface. There is no significant effect toxicity compared with other line-capsule reported...
<b><i>Introduction:</i></b> This prospective study evaluated a calcineurin inhibitor-free graft-versus-host disease (GVHD) prophylaxis regimen of ruxolitinib in combination with post-transplant cyclophosphamide (PTCy). <b><i>Patents and Methods:</i></b> Twenty patients primary or secondary myelofibrosis were prospectively enrolled. Reduced intensity conditioning was performed, followed by allogeneic stem cell transplantation from related...
To date, the impact of tumor microenvironment on prognosis patients with classic Hodgkin lymphoma (cHL) during anti-PD-1 therapy has been studied insufficiently. This retrospective study included 61 primary samples lymph nodes from who had relapsed/refractory (r/r) cHL and were treated nivolumab. Repeated obtained in 15 at relapse or disease progression after immunotherapy. Median follow-up was 55 (13-63) months. The best overall response rate progression-free survival (PFS) analyzed...
Abstract The current incidence, diagnostic policy, management, and outcome of VOD/SOS at EBMT centers were studied. All that had performed allogeneic HSCTs in adult patients within one defined year invited to the study. Seventy-one participated with a total 2886 transplantations 93 cases 2018. cumulative incidence day 21 was 1.8% 100 2.4%. Of 67 detailed data, 52 classical 15 (22%) late onset (>day 21). According criteria, 65/67 least two risk factors. severity grades were: mild 0,...
Chimeric antigen receptor (CAR) T cells are in standard clinical use to treat relapsed or refractory hematologic malignancies, such as non-Hodgkin lymphoma, multiple myeloma and acute lymphoblastic leukemia. Owing the rapidly progressing field of CAR T-cell therapy lack generally accepted treatment guidelines, we hypothesized significant differences between European centers prevention, diagnosis management short- long-term complications. To capture current among Society for Blood Marrow...
There is no consensus on second allogeneic stem cell transplantation (alloSCT) indications in patients with hematologic malignancies relapsing after a first alloSCT. In historic publications, very high non-relapse mortality (NRM) has been described, arguing against performing We analysed the outcome of 3356 alloSCTs performed 2011-21 following malignancy relapse. Outcomes at two years alloSCT were: NRM 22%, relapse incidence 50%, overall survival 38%, and progression-free 28%. Key risk...
The introduction of nivolumab has changed the landscape relapsed/refractory classical Hodgkin lymphoma (r/r cHL) treatment. Despite its clinical importance, this therapy may remain inaccessible for a significant number patients worldwide, especially in low-income countries, due to high cost. results pharmacokinetic analysis and observations suggest potential efficacy low dose r/r cHL patients. aim trial was assess safety at fixed 40 mg with cHL. study included 30 cHL, treated every 2 weeks....